NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING

Transcription

1 NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING RADICAL PROSTATECTOMY IN PATIENTS WITH STAGE T2 PROSTATIC CANCER Takeshi Uedal, Hiroomi Nakatsul, Shigeo Isaka2 and Jun Shimazaki2 1Urology, Kumagaya General Hospital, Saitama, Japan 2'Department of Urology, School of Medicine, Chiba University, Chiba, Japan Radical prostatectomy is the effective treatment for clinical T2 prostatic cancer. However, clinical T2 stage is often understaged preoperatively. The objective of neoadjuvant therapy is to increase the curability of surgery to understaged patients. The present study was based on patients who had had neoadjuvant endocrine therapy (LH-RH agonist) prior to radical nervesparing prostatectomy for T2 prostatic cancer. Sexual function were estimated before and after surgery. Ten patients with a mean age of years (range years) and biopsy-proven cancer received this treatment modality. No patients had evidence of lymph node metastasis by the pelvic computerized tomography and their bone scan was negative for metastasis. Clinical stage was T2a in 3 patients and T2b in 7. The grade of these tumors as assessed on prostatic biopsy before neoadjuvant endocrine treatment was well differentiated in 3 and moderately differentiated in 7. The duration of neoadjuvant endocrine therapy was 3. 6 months (range 2--5 months) in average. Serum levels of prostatic specific antigen (PSA) were examinated monthly and prostate volume was measured by transrectal ultrasonography before and after neoadjuvant treatment. Decrease in serum PSA values was observed from an average level of 8. 6 ng/ml (range ng/ml) determined prior to neoadjuvant treatment to an average of 1. 1 ng/ml (range ng/ml) determined after neoadjuvant treatment. An average reduction of prostatic volume was 25. 3% (range %) after neoadjuvant therapy. Pathological effects of the neoadjuvant therapy by the criteria proposed by Japanese Urological Association were Grade (G) Oa in 3 patients, GOb in 4, G1 in 2 and G2 in 1. Of patients who had 10 stage T2 cancer before treatment, 4 had pt2 and 6 pt3. Of six patients who had pt3 cancer, 5 had capsular invasion, 2 positive surgical margins, 2 seminal vescicle invasion and one positive lymph node. Data of the sexual function before (all cases) and after surgery (only pt2b patients) were obtained by a questionnaire regarding 8 questions. All 10 patients were potent preoperatively. Four patients with pt2 cancer did not receive anticancer therapy after surgery. Of the 4 patients, two patients were able to have sexual intercourse and one could obtain penile erection. One patient with pt3 relapsed after seven months, but the other nine patients were alive without disease.

2 Key words: T2 prostatic cancer, neoadjuvant endocrine therapy, radical nerve-sparing prostatectomy PS: performance status

3 cap: capsule, sv: seminal vescicle, margin: surgical margin

4

5 1) Leandri, P., Rossignol, G., Gautier, JR. and Ramon, J.: Radical retropubic prostatectomy: Morbidity and quality of life. Experience with 620 consecutive cases. J. Urol., 147, , ) Pontes, J. E., Wajsman, Z., Huben, R. P., Wolf, R. M. and Englander, L. S.: Prognostic factors in localized prostatic carcinoma. J. Urol., 134, , 1985, 3) Fowler, J. E. Jr. and Mills, S. E.: Operable Prostatic carcinoma: Coreelations among clinical stage, pathological stage, gleason histological score and early disease-free survival. J. Urol., 133, 49-52, ) Catalona, W. J. and Bigg, S. W.: Never-sparing radical prostatectomy: Evaluation of result after 250 patients. J. Urol., 143, , ) Bigg, S. W., Kavoussi, L. R. and Catalona, W. J.: Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. J. Urol., 144, , ) Monfette, G., Dupont, A., Boivin, J. C. and Tetu, B.: Multiple advantages prior and postprostatectomy with combined endocrine therapy. Abstr. Sess. 22, Round table prostate cancer. 9th Congr. Eur. Ass. Urol. Amsterdam Eur. Urol., 18, 97, ) Fair, W. R., Aprikian, A., Sogani, P., Reuter, V. and Whitemore, W. F.: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer, 71, , ) Frei, E. 3rd.: Curative cancer chemotherapy. Can. Res., 45, , ) Gutierrez, R.: Horizons in the surgical management of carcinoma of the prostate gland. Am. J. Surg., 78, , 1949, 12) Flamm, J., Fisher, M., Holtl, W., Pfluger, H. and Tomschi, W.: Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate. Eur. Urol., 19, , 1991, 13) Macfarlane, M. T., Abi-Aad, A., Stein, A., Danella, J., Belldegrun, A. and Kernion, J. B.: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J. Urol., 150, , ) Haggman, M., Hellstrom, M., Aus, G., Pederso, K., Wijkstorm, H., Stege, R., Elivin, A., Tisell, A., Torre, M., Busch, C. and Brandstedt, S.: Neoadjuvant GnRH-agonist treatment (Triptorelin and Cyproterne acetata for Flare Protection) and Total prostatectomy. Eur. Urol., 24, , 1993, 15) Isaka, S., Shimazaki, J., Akimoto, S., Okada, K., Yoshida, 0., Arai, Y., Usami, M., Kotake, T., Tobisu, K., Kakizoe, T., Ohashi, Y. and Sumiyoshi, Y.: Prospective randomized trial for treatment of stages B2 and C prostate cancer: Radical surgery or irradiation with common endocrine therapy. Jpn. J. Clin. Oncol. (in press) 16) Murphy, W. M., Soloway, MS. and Barrows, G. H.: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer, 68, , ) Tetu, B., Srigley, JR., Boivin, J. C., Dupont, A., Monfette, G., Pinault, S. and Labrie, F.: Effect of combination therapy (LH-RH agonist and Flutamide) on normal prostate and prostatic adenocarcinoma. Am. J. Surg. Pathol. 15, , 1991.

6 20) Sassine, A. M. and Schlman, C.: Role du traitement neoadjuvant avant la prostatectomie radicale. Acta Urol. Belgica, 60, 60-71, ) Isaka, S., Teshima, S., Akakura, K., Igarashi, T., Murakami, S. and Shimazaki, J.: Histological effect of endcrine therapy for prostatic cancer in relation to clinical course. Jpn. J. Clin. Oncol., 19, , ) Peeling, W. B.: Phase 3 studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology, 33, 45-52, ) Walsh, P. C.: Radical prostatectomy, preservation of sexal function, cancer control. Urol. Clini. North Am., 14, , ) O'Donnell, P. D. and Finan, B. F.: Continence following nerve-sparing radical prostatectomy. 1. Urol., 142, , 1989.